Considerations for developing scalable and efficient collection network processes
Cell & Gene Therapy Insights 2021; 7(12), 1766–1773
Many crucial considerations impact a cell and gene therapy developer’s apheresis center selection strategy and ability to efficiently scale processes. Anytime collection processes or protocols differ from those in place at a center, there are likely implications for training, forms, and standard operating procedures (SOPs), which can potentially delay the first collection. In this panel discussion, three experts answer questions on apheresis center best practices within the allogeneic product collection pathway.